Unum Therapeutics transfers BOXR cell-based therapy to Sotio

By The Science Advisory Board staff writers

September 1, 2020 -- Unum Therapeutics has sold its Bolt-on Chimeric Receptor (BOXR) cell-based therapy technology to immuno-oncology firm Sotio.

Sotio will pay $8.1 million upfront for the BOXR technology and assume development of Unum's lead candidate, BOXR1030. Unum will also be eligible for future milestone payments of up to $3.4 million. The deal closed on August 28.

As part of the agreement, Sotio will assume responsibility for a portion of Unum's facilities in Cambridge, MA, to advance the BOXR programs. In addition, certain Unum staff associated with the BOXR programs will transition to Sotio.

Meanwhile, Unum said it has retained its antibody-coupled T cell receptor (ACTR) technology and continues to explore strategic opportunities for its technology and assets. It will also retain certain staff and space in its Cambridge facilities as it refocuses on the development of small-molecule precision kinase inhibitors, including its PLX9486 lead program. Unum said it will reinvest the net proceeds of the BOXR sale into the development of PLX9486.

In other company news, Unum has appointed Peter Harwin as its board chair. Harwin is co-founder and managing member of Fairmount Funds Management, and also played an integral role in Unum's recent acquisition of Kiq, according to the firm.

Harbour BioMed, Vir to develop new therapies
Harbour Biomed and Vir Biotechnology have partnered to research and develop novel immuno-oncology and infectious disease therapies.
Eli Lilly, Innovent expand immuno-oncology licensing
Eli Lilly and Innovent Biologics have agreed to a global expansion of their strategic alliance for Tyvyt (sintilimab injection), an anti-programmed cell...
Biosimulation can mitigate risk of COVID-19 drug development
Drug development can be an expensive and tedious process. Add in the urgency of the COVID-19 pandemic, and you have a recipe for frustration. Biosimulation...
Twist Bioscience, Seismic Bio partner to discover bispecific antibodies
Twist Bioscience and Seismic Bio have formed a partnership to discover and optimize antibodies to high-value immuno-oncology targets.
Thermo Fisher to develop, manufacture next-gen immunotherapy
Thermo Fisher Scientific has formed a strategic partnership with PharmAbcine for the development and manufacturing of PMC-309, a next-generation immune...

Copyright © 2020 scienceboard.net

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter